Bi Xinyu, Lu Yinying, Chen Bo, Yang Zhengqiang, Hong Zhixian, Wang Hanping, Sun Yongkun, Wang Xiaodong, Yuan Chunwang, Zeng Daobing, Huang Zhen, Zhou Aiping, Zhang Wen, Du Shunda, Zhao Jianjun, Zhou Jianguo, Zhai Yirui, Che Xu, Zhao Hong, Zhao Haitao, Cai Jianqiang
Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Comprehensive Liver Cancer Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Liver Cancer. 2024 Oct 21;14(3):334-350. doi: 10.1159/000540857. eCollection 2025 Jun.
Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality; it ranks as the second most common cause of cancer deaths in China. Most HCC patients are first diagnosed at an advanced stage. In recent years, targeted therapy combined with immunotherapy has become the preferred regimen for systemic treatment of intermediate-advanced HCC, while targeted therapy combined with immunotherapy plus local treatment could further improve the efficacy in many clinical studies. To better guide the clinical treatment for effective and safe combination therapy, our interdisciplinary panel on the treatment of intermediate-advanced HCC comprising hepatologists, hepatobiliary surgeons, oncologists, radiologists, interventional radiologists, and traditional Chinese medicine physicians have formulated this consensus based on current clinical studies and clinical medication experience for reference. The consensus contained 15 recommendations, including the applicable population and management, local treatment selection, conversion strategy, treatment strategy after tumor progression and management of common adverse reactions.
肝细胞癌（HCC）是癌症相关死亡的主要原因；在中国，它是癌症死亡的第二大常见原因。大多数HCC患者首次诊断时已处于晚期。近年来，靶向治疗联合免疫治疗已成为中晚期HCC全身治疗的首选方案，而在许多临床研究中，靶向治疗联合免疫治疗加局部治疗可进一步提高疗效。为了更好地指导有效且安全的联合治疗的临床实践，我们由肝病学家、肝胆外科医生、肿瘤学家、放射科医生、介入放射科医生和中医师组成的中晚期HCC治疗跨学科小组，根据当前临床研究和临床用药经验制定了本共识以供参考。该共识包含15条建议，包括适用人群及管理、局部治疗选择、转化策略、肿瘤进展后的治疗策略以及常见不良反应的管理。
